Human lives
drive our discovery
of microbiome therapeutics

Finch is a clinical-stage microbiome therapeutics company

leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs.

Human-First Discovery platform

Our platform is built to rapidly translate insights mined from compelling human data into the development of novel microbiome therapeutics.

Learn more


We are developing a pipeline of microbiome therapeutics targeting gastrointestinal diseases and conditions that extend beyond the gut, with a candidate in late-stage clinical development for recurrent C. difficile, and candidates for inflammatory bowel disease, autism spectrum disorder, and chronic hepatitis B in pre-clinical development.

Learn more

Recent news

Finch Therapeutics to Participate in Upcoming Investor Conferences

November 11, 2021

Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

November 10, 2021

Finch Therapeutics Announces Transition of Chief Medical Officer

November 10, 2021

Join us

Join us in our mission to transform the lives of patients and families fighting serious medical conditions.

Learn more